James Woodruff, Chief Scientific Officer at MapLight Therapeutics, Inc. (), engaged in a series of stock sales totaling approximately $673,636 between July 15 and July 17, 2026. These transactions involved the disposition of voting common stock at prices ranging from $36.00 to $37.96 per share. The sales came after a remarkable run for the stock, which has surged 112% over the past six months and currently trades at $35.99, near its 52-week high of $40.43.
The sales, which amounted to 18,267 shares, were executed to fulfill statutory tax withholding obligations tied to the vesting of restricted stock units. According to the filing, these dispositions were mandated by the company’s equity incentive plans and do not represent discretionary sales by Mr. Woodruff. Following these transactions, Mr. Woodruff directly holds 224,462 shares of MapLight Therapeutics voting common stock. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. Investors can access 12 additional InvestingPro Tips for MPLT, including detailed profitability and financial health insights.
In other recent news, MapLight Therapeutics has seen several significant developments. The company reported top-line results from its Phase 2 IRIS study of ML-004 for autism spectrum disorder, involving 161 participants. Analysts have responded positively, with H.C. Wainwright maintaining a Buy rating and a $45 price target on MapLight Therapeutics following these results. Similarly, Needham raised its price target to $45, citing increased probability of success for the company’s lead candidate, ML-007-MC, for schizophrenia. Raymond James initiated coverage with a strong buy rating and a $46 price target, noting the favorable risk/reward scenario for ML-007C-MA’s Phase 2 ZEPHYR readout.
Additionally, MapLight Therapeutics announced the appointment of Martin Babler and Troy Cox to its Board of Directors, following their election at the company’s Annual Meeting of Stockholders. Babler will join the Audit Committee, while Cox will serve as Chair of the Nominating and Corporate Governance Committee. These appointments come after the departure of Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who did not stand for re-election. The company’s focus on the muscarinic receptor activation mechanism has garnered attention from experts, as discussed during a panel hosted by H.C. Wainwright.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.